| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies (NCT07648264) | CSL Behring | 2026-07-24 |
| Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) (NCT07326592) | CSL Behring | 2026-07-20 |
| Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) (NCT07224360) | CSL Behring | 2026-02-02 |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis (NCT07332091) | CSL Behring | 2026-01-22 |
| Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) (NCT07094087) | CSL Behring | 2025-09-15 |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) (NCT07048262) | CSL Behring | 2025-09-03 |
| Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis (NCT06699849) | CSL Behring | 2025-08-07 |
| Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B (NCT07080905) | CSL Behring | 2025-07-28 |
| A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) (NCT07001280) | CSL Behring | 2025-07-21 |
| An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) (NCT07076446) | CSL Behring | 2025-07-15 |
| Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults (NCT06996184) | CSL Behring | 2025-05-27 |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab (NCT06806657) | CSL Behring | 2025-04-28 |
| Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products (NCT06738485) | CSL Behring | 2025-01-09 |
| Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults (NCT06726863) | CSL Behring | 2024-11-22 |
| Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery (NCT06617897) | CSL Behring | 2024-10-01 |
| Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS (NCT06524739) | CSL Behring | 2024-08-28 |
| Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy (NCT06399289) | CSL Behring | 2024-07-28 |
| Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) (NCT06003387) | CSL Behring | 2024-01-30 |
| First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects (NCT05937581) | CSL Behring | 2023-09-28 |
| Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222) (NCT05962398) | CSL Behring | 2023-08-30 |
| An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (NCT06008938) | CSL Behring | 2023-06-15 |
| CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema (NCT05819775) | CSL Behring | 2023-05-30 |
| Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) (NCT05568888) | CSL Behring | 2023-03-28 |
| Effects of CSL324 in the Lung After Segmental Challenge (NCT05653713) | CSL Behring | 2022-12-20 |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) (NCT05485961) | CSL Behring | 2022-10-21 |
| Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection (NCT05452317) | CSL Behring | 2022-07-14 |
| Hizentra® in Inflammatory Neuropathies - pHeNIx Study (NCT04672733) | CSL Behring | 2022-06-10 |
| A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects (NCT05306275) | CSL Behring | 2022-04-04 |
| Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis (NCT05130970) | CSL Behring | 2022-02-03 |
| Observatory of Patients With Haemophilia B Treated by IdElvion® (NCT05086575) | CSL Behring | 2021-12-03 |
| Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease (NCT04285827) | CSL Behring | 2021-05-20 |
| Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks (NCT04739059) | CSL Behring | 2021-03-29 |
| Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B (NCT05360706) | CSL Behring | 2021-03-18 |
| Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects (NCT04638634) | CSL Behring | 2021-02-02 |
| CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks (NCT04656418) | CSL Behring | 2021-01-27 |
| Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) (NCT04643587) | CSL Behring | 2020-12-07 |
| A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults (NCT04580654) | CSL Behring | 2020-10-29 |
| Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects (NCT04570267) | CSL Behring | 2020-10-08 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects (NCT04446000) | CSL Behring | 2020-09-23 |
| Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease (NCT04419467) | CSL Behring | 2020-09-14 |
| CSL324 in COVID-19 (NCT04519424) | CSL Behring | 2020-09-01 |
| A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line (NCT04281524) | CSL Behring | 2020-03-01 |
| Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (NCT04167514) | CSL Behring | 2020-01-09 |
| Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) (NCT04138485) | CSL Behring | 2019-12-20 |
| A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers (NCT04082754) | CSL Behring | 2019-11-28 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (NCT04044690) | CSL Behring | 2019-10-21 |
| Respreeza® Self-administration and Learning Program (AmAREtTI Study) (NCT04262284) | CSL Behring | 2019-10-18 |
| Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (NCT03744910) | CSL Behring | 2019-10-14 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) (NCT04137224) | CSL Behring | 2019-09-19 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (NCT03805789) | CSL Behring | 2019-03-27 |
| Two Dose Levels of Privigen in Pediatric CIDP (NCT03684018) | CSL Behring | 2019-02-28 |
| A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) (NCT03712228) | CSL Behring | 2018-10-29 |
| Register of Patients With haEmophilia A tReated With Afstyla® (NCT04675541) | CSL Behring | 2018-09-24 |
| Dose Confirmation Trial of AAV5-hFIXco-Padua (NCT03489291) | CSL Behring | 2018-07-24 |
| HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients (NCT03569891) | CSL Behring | 2018-06-27 |
| Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (NCT03473223) | CSL Behring | 2018-03-21 |
| Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults (NCT03375606) | CSL Behring | 2018-01-10 |
| Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (NCT03779828) | CSL Behring | 2017-11-27 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients (NCT03221842) | CSL Behring | 2017-11-06 |